Carpal tunnel syndrome (CTS) occurs when the median nerve is compressed at the wrist in the carpal tunnel. It has been suggested that hormonal risk factors may be involved in the pathogenesis of CTS, and a higher incidence of CTS has been reported in randomized clinical trials with aromatase inhibitors (AIs) compared with tamoxifen.
INTRODUCTION
Carpal tunnel syndrome (CTS) occurs when the median nerve, which runs from the forearm into the hand, is compressed in the carpal tunnel, an osteofibrous, not extensible outlet at the wrist. It is the most common entrapment neuropathy and in most cases is idiopathic. Secondary CTS may be caused by abnormalities of the shape or position of the carpal bones surrounding the tunnel (eg, acromegaly and osteoarthritis) or by the contents of the tunnel (such as synovial hypertrophy, intracanalicular tumors, inflammatory or metabolic tenosynovitis, or abnormal fluid distribution such as in pregnancy). 1 Diagnosis of CTS is mainly clinical, 1 with nocturnal acroparaesthesia being the most sensitive symptom.
2 Paraesthesia in median nerve territory is described as needles, burning sensation, tingling, heaviness, or electric impulses, usually accompanied by pain radiating to the forearm, elbow, or shoulder. Other symptoms include a decrease in strength, morning edema, and cold intolerance. 1 Additional tests such as nerve conduction studies are not essential for the diagnosis of a typical form of CTS and do not provide any additional evidence compared with clinical assessment.
developing CTS compared with men, especially around the time of menopause. 4, 5 Pregnancy, 6 bilateral oophorectomy, 7 and use of the combined oral contraceptive 8 have all been identified as risk factors for CTS. In contrast, menopausal hormone replacement therapy (MHT) has been shown to lead to resolution of CTS in menopausal women. 9, 10 Increased risk of CTS has also been reported with third-generation aromatase inhibitors (AIs) anastrozole, 11 exemestane, 12 and letrozole, 13 which have become established adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer, because they have been shown to significantly lower recurrence rates compared with tamoxifen. 14 In addition, the International Breast Cancer Intervention Study (IBIS)-II and Mammary Prevention (MAP) 3 trials showed the effectiveness of anastrozole and exemestane in preventing breast cancer in healthy postmenopausal women at high risk of developing the disease. 15, 16 However, musculoskeletal symptoms have been reported significantly more often with AIs when compared with tamoxifen or placebo 17,18 and may account for nonadherence to treatment, which has been reported to be as high as 25% during the first year of therapy. 19 In a multicenter, prospective trial of exemestane versus letrozole, 24.3% discontinued therapy because of musculoskeletal symptoms. 20 With many patients with breast cancer taking AIs worldwide, adverse effects that can limit compliance are of growing importance. Available data on CTS and AIs come from clinical studies against tamoxifen in the adjuvant setting. Here, we investigate the characteristics of CTS in women taking anastrozole who are at high risk of developing breast cancer (IBIS-II trial), 15 without the limitation of the possible confounding effect of tamoxifen or other breast cancer treatments.
PATIENTS AND METHODS
The IBIS-II study 15 is a double-blind randomized clinical trial in which women at increased risk of breast cancer were randomly assigned to receive oral anastrozole (1 mg/day) or matching placebo for 5 years. Details of trial design, methods, study population, objectives, and results have been described previously. 15 All participants provided written informed consent before trial entry. Regulatory authorities and ethics committees for all participating centers in 18 countries approved the protocol before enrollment of participants. The trial was performed in accordance with the Declaration of Helsinki (1996 revision) and under the principles of Good Clinical Practice. The IBIS-II trial is registered as an International Standard Randomized Controlled Trial (No. ISRCTN31488319). The study has completed accrual (n = 3,864), and follow-up is continuing for enrolled participants.
Patients were included in this analysis if CTS, as reported by the investigator on case report forms, or CTS symptoms occurred at any time during active treatment. CTS symptoms were defined as follows: paraesthesia in the median nerve territory described as needles, burning sensation, tingling, heaviness, or electric impulses usually accompanied by pain radiating to the forearm, elbow or shoulder, decrease of strength, or swelling.
This analysis was based on an intention-to-treat population. One patient was excluded because of CTS at baseline. Analyses of potential risk factors (treatment, age, smoking status, previous MHT use, body mass index [BMI] , and other musculoskeletal symptoms [arthralgia]) were based on comparisons of proportions by univariate and multivariate logistic regression (adjusted for all baseline factors). Interactions between treatment and subgroups were based on likelihood ratio tests for an added interaction term. Annual hazard plots were also produced. All P values are two sided, with level of significance at P = .05 and all CIs are at the 95% level. All calculations were performed by use of STATA (version 12.1; STATA, College Station, TX).
RESULTS
A total of 3,864 women were randomly assigned to receive either anastrozole (n = 1,920) or placebo (n = 1,944). Baseline characteristics are listed in Table 1 and were described in detail elsewhere. 15 In brief, median age was 59.5 years (interquartile range [IQR], 55.0 to 63.5 years), and almost half of the women (47%) had used MHT previously. The majority of the women had a BMI of greater than 25 kg/m 2 (69%) and half of the women were neversmokers (Table 1) . Patients' characteristics were well balanced between the two treatment arms (Table 1) Figure 1 shows a histogram of newly reported CTS according to treatment arm. Newly reported CTS was higher in the anastrozole arm compared with placebo over the entire course of active treatment, but the difference was particularly evident during the first 2.5 years of treatment (Fig 1) .
Women in the anastrozole arm tended to have more severe disease (P for trend = .09). A total of 10 cases of CTS (0.3%) were reported as severe: eight (0.4%) in the anastrozole arm and two (0.1%) in the placebo arm ( Table 1 ). The rate of severe CTS in the anastrozole arm was four times higher compared with the placebo arm, but the difference was statistically not significant (OR, 4.06 (0.86 to 19.16); P = .076). A modest difference in intensity according to treatment arm was also noted for moderate severity, with 17 participants (0.9%) in the anastrozole arm compared with 10 participants (0.5%) in the placebo arm (OR, 1.73 [0.79 to 3.78], P = .1). Reports of mild CTS were similar between the two treatment groups (Table 2) . Thirty-two women (0.8%) reported bilateral CTS and similarly, 31 women (0.8%) reported unilateral CTS (Table 2) . No significant differences between treatment arms and laterality were observed (Table 2) .
Although only 38 women (1.0%) had some sort of treatment of CTS, the difference between the two treatment arms was statistically significant (OR, 2.21 [1.11 to 4.39], P = .024) ( were managed with a conservative approach (ie, cortisone injections [n = 13] and/or wrist splint [n = 11]). There was no difference between the two treatment arms according to conservative treatment of CTS (Table 2) . Median time to resolution was 1.00 year (IQR, 0.27 to 2.07 years), with no significant differences found between treatment arms (P = .4). Treatment was discontinued in a total of 17 women because of the onset of CTS or other adverse events (12 anastrozole v five placebo; OR, 2.44 [0.80 to 8.85]; P = .08).
Potential risk factors for developing CTS were analyzed and are summarized in Table 3 Number of CTS 
DISCUSSION
To our knowledge, this is the first analysis of CTS characteristics and risk factors in healthy, postmenopausal women taking anastrozole in a large, randomized, placebo-controlled trial. Two previous studies reported comparative data for anastrozole 11 and exemestane, 12 but the comparator was tamoxifen. Our results show a twofold increase in CTS for women who were randomly assigned to anastrozole when compared with placebo.
A higher rate of CTS was observed in this retrospective analysis of the IBIS-II trial (3.4% anastrozole and 1.6% placebo) compared with the Arimidex, Tamoxifen, Alone or in Combination (ATAC; 2.6% anastrozole and 0.7% tamoxifen) and Intergroup Exemestane Study (IES; 2.8% exemestane and 0.6% tamoxifen) studies. This may be a consequence of an increased awareness of this adverse effect by both investigators and patients that led to a more precise reporting of symptoms. The majority of cases of CTS in those taking anastrozole in our study were reported early on (0 to 24 months), and the incidence of newly reported CTS decreased thereafter. A similar picture was seen in the ATAC trial, in which most cases of CTS in those taking anastrozole were reported within the first 2 years, and a decline was seen thereafter.
11
Overall, the incidence of CTS with anastrozole was low (3.4%) and fewer than two of every 1,000 women discontinued treatment only because of the onset of CTS. In fact, the majority of CTS reported in the anastrozole group was of mild to moderate severity, with approximately 10% of participants reported as severe and one out of three requiring an intervention of any kind (surgery or corticosteroids/wrist splint). The natural evolution of CTS is usually slow progression, but symptoms may regress spontaneously in approximately one-third of patients. 1, 21 In a large multicenter study, 34% of patients improved without any intervention, and 45% were unchanged after 1 year without any treatment and with a short duration of symptoms being the main favorable prognostic factor. 22 In the ATAC trial, 11 the rate of surgical interventions was 13%, which was lower than our finding of 25%. In contrast, the IES trial observed a rate of surgeries as high as 69%.
12 There is no evidence for a differential activity of these two drugs that can explain this discrepancy.
23,24 However, the higher risk of developing CTS (OR, 5.33 v OR, 2.16 to 3.55) and the higher rate of surgical procedures (69% v 13% to 25%) observed with exemestane suggest that the risk and severity of CTS may be higher with exemestane than with anastrozole. The management of CTS was not reported uniformly because it was left to the scrutiny of local investigators and the diagnosis is mainly clinical, so the differences between the two classes of AIs may be the consequence of a different approach in reporting and treating this condition.
The pathophysiology of CTS with AIs has yet to be described fully. Studies on biochemical markers of autoimmunity and inflammation show no evidence of a systemic autoimmune/ inflammatory process in the pathogenesis of CTS and other musculoskeletal symptoms. 25, 26 Estrogen deprivation has been hypothesized to be the main explanation for the development of CTS, 27 as well as other musculoskeletal symptoms. AIs reduce estrogen levels in postmenopausal women, blocking the peripheral conversion of androgenic precursors into estrogen by the aromatase enzyme. Estrogen is known to have antinociceptive effects, 28 and Felson and Cummings 29 reported increased pain-related symptoms in women taking an AI; they argue that this may be a consequence of a decreased threshold for pain stimuli. Other investigators 30 have found that estrogen and progesterone receptors are expressed in the transverse carpal ligament, which forms the roof of the carpal tunnel, and have suggested that female sex hormones may influence the transverse carpal ligament metabolism and directly induce CTS. Morphologic changes in the carpal tunnel contents, such as thickening of the tendon sheaths and the presence of intra-articular fluid, have been reported consistently in different studies 25, 26, 31 and could lead to CTS increasing the intracompartmental pressure. In our analysis, we found an association between CTS and other musculoskeletal symptoms. In a study on women taking adjuvant AIs compared with women who were not, more patients with AI-related arthralgia had findings consistent with CTS than did those without arthralgia, suggesting that the induction of CTS by AIs may share the same mechanisms of other musculoskeletal symptoms.
26
Our study has some limitations. Data on the severity and date of resolution of CTS were missing for several women, even after specific inquiries. Diagnosis, management and reporting of CTS were left to local investigators and were therefore heterogeneous, and full clinical details were not captured. Nevertheless, this should not bias our comparative analysis because the study was double blinded, so neither the investigator nor the patient was aware of the treatment. Median follow-up is more than 6 years, and because most cases occur early in the treatment period, we will have captured almost all of the treatment-related cases.
In summary, the use of anastrozole was associated with a higher incidence of CTS, with an excess incidence of 1.8% after treatment completion. Most CTS cases were of mild to moderate intensity, and only 0.8% of women taking anastrozole required surgical intervention. Further investigations are warranted that examine the risk factors for CTS, the musculoskeletal symptoms after AI treatment, and the ways in which CTS can be avoided or ameliorated.
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